JP2023549079A5 - - Google Patents
Info
- Publication number
- JP2023549079A5 JP2023549079A5 JP2023526252A JP2023526252A JP2023549079A5 JP 2023549079 A5 JP2023549079 A5 JP 2023549079A5 JP 2023526252 A JP2023526252 A JP 2023526252A JP 2023526252 A JP2023526252 A JP 2023526252A JP 2023549079 A5 JP2023549079 A5 JP 2023549079A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063108047P | 2020-10-30 | 2020-10-30 | |
| US63/108,047 | 2020-10-30 | ||
| PCT/US2021/057407 WO2022094314A1 (en) | 2020-10-30 | 2021-10-29 | Dual targeting chimeric antigen receptors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023549079A JP2023549079A (ja) | 2023-11-22 |
| JPWO2022094314A5 JPWO2022094314A5 (https=) | 2024-11-07 |
| JP2023549079A5 true JP2023549079A5 (https=) | 2024-11-07 |
Family
ID=81383292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023526252A Pending JP2023549079A (ja) | 2020-10-30 | 2021-10-29 | 二重標的化キメラ抗原受容体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240108721A1 (https=) |
| EP (1) | EP4237543A4 (https=) |
| JP (1) | JP2023549079A (https=) |
| AU (1) | AU2021368741A1 (https=) |
| CA (1) | CA3200265A1 (https=) |
| WO (1) | WO2022094314A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024121414A1 (en) * | 2022-12-08 | 2024-06-13 | Université De Genève | Chimeric antigen receptor |
| WO2025252993A1 (en) * | 2024-06-07 | 2025-12-11 | Université De Genève | Chimeric antigen receptor targeting glioma-associated antigens |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013040557A2 (en) * | 2011-09-16 | 2013-03-21 | The Trustees Of The University Of Pennsylvania | Rna engineered t cells for the treatment of cancer |
| WO2014055657A1 (en) * | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| WO2016123143A1 (en) * | 2015-01-26 | 2016-08-04 | The University Of Chicago | CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Rα2 |
| US20180258149A1 (en) * | 2015-09-17 | 2018-09-13 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| EP4282969A3 (en) * | 2016-09-02 | 2024-01-31 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with duocars |
| WO2018183888A2 (en) * | 2017-03-31 | 2018-10-04 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling |
| CN113811327A (zh) * | 2019-03-11 | 2021-12-17 | 卢西德生物有限公司 | MUC1平行CAR(pCAR)治疗剂 |
| EP4021485A1 (en) * | 2019-08-28 | 2022-07-06 | King's College London | B cell targeted parallel car (pcar) therapeutic agents |
| EP4136119A4 (en) * | 2020-04-17 | 2024-09-11 | Regeneron Pharmaceuticals, Inc. | MODIFIED CCR POLYPEPTIDES AND USES THEREOF |
-
2021
- 2021-10-29 AU AU2021368741A patent/AU2021368741A1/en active Pending
- 2021-10-29 US US18/034,669 patent/US20240108721A1/en active Pending
- 2021-10-29 WO PCT/US2021/057407 patent/WO2022094314A1/en not_active Ceased
- 2021-10-29 EP EP21887657.1A patent/EP4237543A4/en active Pending
- 2021-10-29 JP JP2023526252A patent/JP2023549079A/ja active Pending
- 2021-10-29 CA CA3200265A patent/CA3200265A1/en active Pending